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ABSTRACT 
Objective: To evaluate the association between a clustering of cardio-metabolic risk factors in parents 
and the development of microalbuminuria (MA) in their offspring with childhood-onset type 1 
diabetes (T1D). 
Methods: The study population comprised 53 parents (mean age (±SD): 56.7±6.2 years) of 35 T1D 
young people with MA (MA+) and 86 parents (age: 56.1±6.3 years) of 50 matched offspring with 
normoalbuminuria (MA–), who underwent clinical, biochemical and cardiovascular imaging 
assessments. The primary study endpoint was the difference between parents from the MA+ and 
MA- groups in a cardio-metabolic risk score, calculated as the average value of the standardized 
measures (z-scores) for waist circumference, blood pressure, fasting glucose, insulin, HDL-
cholesterol and triglycerides levels. Cardiovascular parameters, including carotid intima-media 
thickness (cIMT), flow-mediated dilatation (FMD) and pulse wave velocity (PWV), were also 
assessed. A DXA scan was performed to assess body composition. 
Results: The cardio-metabolic risk score was significantly higher in parents of MA+ compared to 
parents of MA- offspring (mean [95% CI]: 1.066[0.076; 2.056] vs -0.268[-0.997; 0.460], p=0.03). 
Parents of MA+ offspring had slightly higher values of waist circumference, lipids, insulin and blood 
pressure, although only diastolic blood pressure was statistically different between the two groups 
(p=0.008). FMD, cIMT, PWV (all p>0.3) and DXA parameters (all p>0.2) were not significantly 
different between the two groups. 
Conclusions: Parents of young offspring with childhood-onset T1D and MA showed an abnormal 
metabolic profile, reflected by a calculated risk score. The finding supports the role of a familial 
predisposition to risk of developing diabetic nephropathy. 
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INTRODUCTION  
Diabetic nephropathy (DN) and cardiovascular disease (CVD) are among the most common 
vascular complications of type 1 diabetes (T1D), which adversely influence the long-term prognosis 
of people with this disease [1–3]. Several studies have shown that premature atherosclerosis 
represents the main cause of morbidity and mortality in patients with T1D [1,4]. Although hard end-
points, such as stroke and ischemic heart disease, are uncommon in children and adolescents with 
T1D, early subclinical structural and functional vascular abnormalities are often found in this age 
group [5,6]. Risk for CVD in patients with T1D is strongly associated with the presence of renal 
disease, as supported by the higher CVD morbidity and mortality in people with increased albumin 
excretion rates [7,8].  
In addition, cardio-metabolic risk factors, such as increased blood pressure and lipid levels, visceral 
adiposity, insulin resistance, impaired glucose tolerance, and their combination, known as metabolic 
syndrome, are strong predictors for CVD risk in the general population and in people with T1D [9–
11]. Based on these data, the investigation of specific cardio-metabolic risk factors and their 
clustering within families has become an appealing research area over the last years. A recent study 
on a large population of 12-year old children and their parents showed that a family history of CVD 
had a key impact on the cardio-metabolic profile of the offspring, thus highlighting the importance of 
identifying CVD risk factors within families for preventive strategies [9]. In adults with T1D a family 
history of hypertension or insulin resistance/type 2 diabetes has been associated with risk of DN in the 
offspring [12–15]. Some studies have also highlighted that a clustering of familial cardio-metabolic 
risk factors could have a stronger effect than individual factors on risk of DN [14].  
Up to now, the association between familial cardio-metabolic risk factors and/or their clustering and 
risk of early stages of DN, such as microalbuminuria (MA), has not been fully assessed in families of 
young people with childhood-onset T1D. Previously, our group was able to replicate some of the 
findings reported in adults with T1D in young cohorts of children and adolescents with T1D, where 
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parental blood pressure emerged to have an independent effect on MA risk in the offspring [16,17]. A 
similar association between parental history of hypertension and MA in the offspring was reported in 
other two previous studies [18,19]. In contrast, we were not able to show any effect of parental lipid 
levels on the risk of MA in the offspring [20].  
The aim of this study was to investigate the association between an aggregation of cardio-metabolic 
risk factors in parents of young people with T1D and the occurrence of MA during adolescence in the 
offspring.  
 
METHODS 
Study design 
This was a nested case-control study within the Nephropathy Family Study (NFS) and Oxford 
Regional Prospective Study (ORPS) cohorts [21,22], where parents of probands with childhood-onset 
T1D were assessed. Cases were parents of T1D probands who had developed MA during childhood 
and adolescence, whereas controls were parents of probands who had not developed MA after a long 
follow-up. Once potential probands with MA were identified, two control probands without MA were 
selected within the same ORPS/NFS cohorts and were matched for age, sex and duration of diabetes 
with the probands with MA. Parents of both groups were approached by sending invitation letters 
together with information leaflets about the study.  
After the parents agreed to take part in the study and after they signed the informed consent they 
underwent a clinical, biochemical and cardiovascular imaging assessment, which were performed 
during two study visits. The study participants were admitted to the Wellcome Trust Clinical 
Research Facility (WTCRF) at Addenbrooke’s Hospital in Cambridge (UK) or at the Oxford Centre 
for Diabetes, Endocrinology and Metabolism (OCDEM) in Oxford (UK), for the first visit. The 
second visit, including vascular imaging assessments, was performed at the Vascular Physiology Unit, 
Great Ormond Street Hospital, in London (UK).  
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The study protocol was approved by the Ethics Committee in Cambridge, UK. The study was carried 
out in conformation with the spirit and the letter of the Declaration of Helsinki and in accordance with 
the guidance in Good Clinical Practice. Written signed informed consent was obtained from the study 
participants before the beginning of the study and any study assessment.   
Study visits 
Visit 1. The first outpatient visit included: 
1. Collection of anthropometric parameters: Height was measured with a wall mounted electrical 
device; weight was taken with an electronic scale and BMI was calculated as weight/height squared 
(kg/m2). Waist circumference was measured midway between the rib cage and the superior border of 
the iliac crest while the subject was standing. Waist circumference was measured 3 times and the 
average of measures was calculated. Anthropometric assessments were performed by trained 
personnel, following the WHO recommendations. 
2. Assessment of blood pressure: Blood pressure was taken in a supine position on both the right and 
left arms using an Omron M6 blood pressure machine (Omron healthcare, Netherlands) after ten 
minutes rest. Three readings were taken each 2 minutes apart and the mean value used in the analysis. 
Adult medium and large size cuffs were used depending on the size of the arm.   
3. Collection of fasting blood samples for measuring glucose, insulin, lipids, HbA1c, CVD markers 
(high-sensitivity C-reactive protein (hs-CRP) and asymmetric dimethylarginine (ADMA)).  
4. Collection of urine samples: All participants were asked to provide three consecutive early morning 
first-voided urine samples for the assessment of the albumin-creatinine ratio (ACR). 
5. Questionnaires data: All parents were asked to fill in a questionnaire assessing history of smoking, 
high cholesterol and cholesterol lowering treatment, hypertension, antihypertensive treatment, 
cardiovascular events (coronary disease, myocardial infarction, and stroke), presence of diabetes. 
6. Dual-energy x-ray absorptiometry (DXA): DXA scans were performed to assess body composition.  
Visit 2:  
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The second study visit included cardiovascular imaging studies assessing carotid intima-media 
thickness (cIMT), endothelial function by flow-mediated dilatation (FMD) and arterial stiffness by 
pulse wave velocity (PWV). 
All vascular scans were performed at the same vascular centre in London by the same sonographers, 
who underwent an accreditation and reproducibility training programme before scanning participants, 
and a single reader analyzed all the scans (HN).  
cIMT: Ultrasound scanning for cIMT was performed with a Vivid 7 (GE Healthcare) using a L7, 5-
10 MHz linear array broadband transducer probe. A standardized protocol was used to acquire 
longitudinal images of the common carotid artery on both the right and left sides. The neck was 
positioned at 45o to the horizontal and the probe held lateral to the neck. Loops of images were 
recorded in DICOM (Digital Imaging and Communications in Medicine) format for 10 heart cycles 
triggered on the R wave of the ECG. The bifurcation of the artery was positioned on the left side of 
the screen and a consistent zoom used so 2 cm of the vessel was viewed and recorded. Measurements 
were taken both at the right and left sides, and the mean between the two measurements was 
calculated and used for the analysis. All image analyses were carried out off-line using vascular 
research tools Carotid Analyser (Medical Imaging Applications, Iowa, USA). The cIMT value was 
measured 10mm posterior to the bifurcation in a 5mm section of the artery as a mean of 3 end 
diastolic cycles.    
FMD: Prior to the FMD scan all participants were asked to avoid caffeine, vitamin C, strenuous 
exercise and tobacco for 6 hours; however, regular medications were continued. Measurements were 
taken in a quiet and temperature controlled room (20-24oC) and a skin temperature ≥30oC was 
required for the test to be carried out. The participants were rested for 10 minutes before 
examination. The right arm was placed in an arm rest fitted with a clamp to hold the ultrasound probe 
in position for the entire experiment. An automated blood pressure cuff was placed around the right 
arm, 1 cm below the antecubital fossa. B-mode ultrasound scans were obtained of the right brachial 
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artery using an Aloka 5500 (Japan) equipped with a 7.5 MHz linear array transducer. The test was 
recorded on VHS and a PC using Imager programme in DICOM format. Ultrasound measurements 
were taken for 1 minute then the cuff was inflated to a pressure of 300mmHg for 5 minutes to restrict 
blood flow to the hand. After 5 minutes of blood flow ischemia the cuff was deflated and 
measurements taken for a further 5 minutes.   
Changes in diameter in the brachial artery were measured off-line. Arterial diameter analysis was 
performed with an automated edge detection system, Brachial Tools (Iowa, USA). The software uses 
an automatic trace of the vessel lumen/wall interface in a 5 mm section of artery with clearly defined 
vessel walls throughout the examination. FMD was expressed as both the absolute difference 
between maximal and resting vessel diameters and as a percentage change of resting diameter. The 
velocity-time integral (VTI) of the pulse wave Doppler signal was used to calculate baseline blood 
flow and reactive hyperemia flow. FMD corrected for shear stress was obtained by dividing FMD by 
the hyperemic VTI [23]. 
PWV: Applanation tonometry SphygmoCor (AtCor Medical, Australia) was used to assess arterial 
stiffness. Participants were rested in a supine position for at least 15 minutes before PWV was 
measured. The tonometer was placed on the pulse points of left carotid and right femoral arteries in 
turn. The pulse pressure waveforms were recorded for 10 seconds and PWV was calculated in 
relation to ECG trace. Distances were measured between pulse points via the suprasternal notch to 
allow the accurate calculation of PWV by the SphygmoCor software.  
 
Laboratory methods 
Blood glucose was measured using an adaption of the hexokinase-glucose-6-phosphate 
dehydrogenase method on a Siemens Dimension analysers (RxL and EXL). 
Plasma insulin concentrations were measured using a DAKO ELISA (DAKO Ltd., Denmark House, 
Angel Drove, Ely, Cambs, UK) according to the manufacturer’s instructions.  
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Lipids: measurements of total cholesterol, high-density lipoprotein (HDL)-cholesterol and 
triglycerides were performed enzymatically on a Dimension RXL system (Dade Behring) using 
reagents and calibrants supplied by the manufacturer.  
hsCRP: was measured in plasma samples by laser immunonephelometry (Dade Behring).  
ADMA: was measured by stable isotope dilution electrospray tandem mass spectrometry, as 
previously described [24].  
HbA1c: samples were centrally on a TOSOH G7 analyzer, using high-performance liquid 
chromatography and absorbance change detection and Diabetes Control and Complications Trial 
(DCCT) aligned methods.  
Urinary albumin and creatinine: were measured centrally as previously described [25].  
 
DXA  
Data on body composition were gathered with a Lunar Prodigy machine using a constant pixel size of 
1.2 x 1.2 cm and Lunar software programs (version 8.1, Lunar Corporation, Madison, WI). The 
effective radiation dose was 0.1 μSievert. The scan yielded measures of whole-body fat and fat-free 
mass (FFM) and therefore percent whole-body fat mass. All DXA scans were performed in 
compliance with local IR(ME)R Employer's Procedures. 
 
Calculations 
Cardio-metabolic risk score: A continuous clustered cardio-metabolic risk score (z-score) was 
computed. This score represents a summary variable for components of metabolic syndrome, which 
gives a standardized estimate and has been used in several studies [26–28]. The cardio-metabolic risk 
score was calculated based on previous studies and included the average value of age and sex-
standardized measures (z-scores) for six outcomes: measures of central obesity (waist 
circumference), dyslipidaemia (triglycerides and HDL-cholesterol), hypertension (systolic and 
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diastolic blood pressure) and glucose metabolism (fasting glucose and insulin). Each variable was 
standardized by calculating sex-specific z-scores (z-score= (individual value-population 
mean)/population SD). Subsequently, individual z scores were summed, after inverting HDL-
cholesterol z scores and averaging systolic and diastolic blood pressure z scores. Adjustments were 
made to take into account presence of diabetes in the parents as well as active treatment for high 
blood pressure or dyslipidaemia, by adding a correcting factor, arbitrary chosen as 0.5 points when 
any of these factors was present. 
 
Study endpoints 
The primary study endpoint was defined as the difference in the continuous cardio-metabolic risk 
score between parents of MA positive and MA negative offspring.  
The secondary endpoints were defined as differences between the two study groups in 1) the 
individual factors of the cardio-metabolic risk score: waist circumference, blood pressure, fasting 
lipids, fasting glucose, fasting insulin; 2) cIMT, FMD and PWV; 3) cardiovascular markers (hsCRP, 
ADMA, ACR); 4) body composition parameters obtained from the DXA scans (total lean and fat 
mass, regional fat mass distribution: gynoid, android, trunk and limbs fat mass). 
Power calculation for the primary endpoint: Assuming a two sample t-test is performed at the 5% 
significance level (2-sided), 40 cases (parents of MA + offspring) and 80 controls (parents of MA- 
offspring) provides 80% power to detect a 0.55 unit difference in primary outcome metabolic z-score 
(assuming mean =0 and SD=1) between the groups.  
 
Statistical methods 
The cardio-metabolic risk score and the individual cardio-metabolic parameters and body composition 
measurements between parents of MA positive and MA negative offspring were compared using a 
two sample unpaired t-test (two tailed). In case of not normally distributed variables, a log base 10 
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transformation was applied before testing. Analysis of covariance was used when adjustments for 
potential confounding factors where required.   
P values <0.05 were taken as statistically significant. Data are expressed as mean ± SD or median 
(interquartile range), unless otherwise stated. Statistical analysis was performed with SPSS version 23 
software for Windows (SPSS, Chicago, IL).  
 
RESULTS 
In total 139 parents of 85 T1D offspring (35 offspring with MA (MA positive) and 50 T1D offspring 
without MA (MA negative)) agreed to take part in the study and attended the two study visits. The 
139 parents (63 fathers and 76 mothers) included 53 parents of MA positive and 86 parents of MA 
negative offspring. For 54 offspring both parents agreed to take part in the study, whereas for the 
remaining 31 only one parent agreed to take part in the study (22 mothers and 9 fathers) (Table 1). 
The general characteristics of the offspring are reported in table 2. 
 
Cardio-metabolic risk score in the parents: MA positive vs MA negative group 
Parents of MA positive offspring were similar in age, height, and BMI compared with parents of MA 
negative offspring (Table 3). 
A significant difference was found in the cardio-metabolic risk score between parents of MA positive 
offspring and parents of MA negative offspring, with higher values in the MA positive group: mean 
[95% CI]: 1.066 [0.076; 2.056] vs -0.268 [-0.997; 0.460], p= 0.03 (Figure 1).  
Parents of MA positive offspring tended to have higher values of the individual components of the 
cardio-metabolic score, such as waist circumference, blood pressure and insulin, although only the 
difference in diastolic blood pressure reached statistical significance (Table 3). 
 
Cardiovascular imaging in parents of MA positive vs MA negative offspring 
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There were no statistically significant differences in the circulating cardiovascular markers ADMA 
and hsCRP between parents of MA positive and MA negative offspring. Similarly, urinary ACR was 
similar between the two groups (Table 3). 
No significant differences were found in the direct cardiovascular measurements including cIMT, 
FMD and PWV, before and after adjusting for potential confounders such as age and sex (Table 4).  
 
Body composition in parents of MA positive vs MA negative offspring 
No significant difference in total fat and lean mass, gynoid, android, limbs and trunk fat mass were 
found between parents of Ma positive and MA negative children (Table 4).   
 
 
DISCUSSION 
In the present nested case-control study within the ORPS/NFS cohorts, a clustering of parental 
cardio-metabolic risk factors, expressed as a cardio-metabolic risk score, was assessed in relation to 
the development of MA in the offspring. The main study finding was that the cardio-metabolic risk 
score was higher in parents of offspring who developed MA during adolescence compared to parents 
of those who did not develop this complication. 
 
Although glycemic control is an important risk factor for renal and other vascular complications of 
T1D, it does not entirely explain risk, particularly during puberty, when hormonal and metabolic 
changes, together with lifestyle, environmental exposures and genetic/familial factors may also 
significantly contribute to the overall complication risk [5,6]. Previously, our group and others have 
shown that during adolescence, in addition to poor glycemic control, factors associated with 
increased albumin excretion and presence of MA are high blood pressure, dyslipidemia, 
inflammatory markers, hyperfiltration [5,6]. Inherited cardio-metabolic risk factors, such as lipid, 
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blood pressure, insulin resistance, obesity, have also been suggested as potential contributing factors 
to the overall risk of developing MA and DN [12–16]. One way for exploring the role of inherited 
factors is assessing them within families. Previous family studies in adults with T1D have reported an 
association between parental CVD risk factors, such as hypertension, insulin resistance and type 2 
diabetes, as well as their clustering, and presence of nephropathy in the offspring [12–15]. Limited 
data are available for young people with childhood-onset T1D [16–20]. In two previous studies, we 
showed an independent effect of parental blood pressure, assessed by 24-hour ambulatory blood 
pressure monitoring, on urinary albumin excretion in young offspring with T1D [16,17]. In contrast, 
parental lipid levels, although being an independent predictor of the same trait in the offspring, did 
not emerge to be a contributing factor for variations in albumin excretion in offspring from the same 
cohorts [17,20].  
In the present study we aimed to extend these findings and assess the effect of a clustering of cardio-
metabolic risk factors on MA risk. Interestingly, the standardized cardio-metabolic risk score we used 
in the study emerged to be higher in parents of offspring with MA. This association could be 
explained by a similar genetic background influencing cardio-metabolic profiles in the parents and 
risk of MA in the offspring. An alternative explanation might be the effect of sharing lifestyle 
behaviors between parents and offspring, which might be a key target for preventive strategies, or the 
effect of shared sociodemographic influences. 
 
Over the last years the use of a continuous cardio-metabolic risk score has been suggested and proved 
to be a valid tool for epidemiological and clinical studies [26–29]. In particular, a continuous cardio-
metabolic risk score can offer some advantages compared to the use of dichotomous variables, such 
as presence or absence of metabolic syndrome. One important advantage is a higher statistical power. 
In addition, a continuous score has been shown to better reflect the fact that cardiovascular risk is a 
progressive function of several risk factors, thus removing problems related to the application of 
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arbitrary cutoffs [29]. In our study the use of the cardio-metabolic score also allowed us to make 
adjustments for specific treatments, such as for hypertension/dyslipidemia or for presence of 
diabetes, which can be common in adult populations, and which can influence comparisons of 
individual data on lipids, blood pressure, glucose/insulin levels.  
Most of the individual components of the cardio-metabolic risk score taken individually tended to be 
higher in parents of offspring with MA than in parents of offspring without this complication, but 
only the difference in diastolic blood pressure reached statistical significance. The latter finding 
confirms previous observations in young people with T1D, where parental blood pressure or a history 
of hypertension was one of the main familial risk factors associated risk of MA in the offspring 
[12,16–19].  
In the present study, no significant differences were found in circulating markers of CVD such as 
hsCRP, ADMA or ACR. Similarly, no differences were found in direct measures of vascular 
structure and function. This could be due to lack of sufficient power to detect changes in these 
parameters, for which differences could be subtler than those seen in the cardio-metabolic risk score, 
and therefore might emerge only with larger sample sizes. Another potential explanation for the lack 
of differences in these specific CVD measures could be that they might emerge later at an older age 
in the parents. Indeed, compared to previous studies assessing families of patients with T1D, parents 
in the present study were younger, with a mean age of around 56 years.  
 
A major strength of the present study was that parents underwent direct assessments during the study 
visits, including collection of anthropometric measurements, blood samples for measuring circulating 
markers of CVD, direct imaging measures of vascular structure and function. In contrast, previous 
studies have been mainly based on collections of family history of cardiovascular events through 
questionnaires or direct interviews [13,30]. 
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One potential limitation of the study was the sample size which was not particularly high, although a 
power calculation was performed and we were able to recruit a sufficient number of subjects to detect 
the expected differences in the primary outcome. As stated above, it could be that the power was not 
enough to detect subtler changes in direct measures of vascular structure and function. Another 
potential study limitation is related to the fact that we were not able to recruit complete mother-father 
pairs for all offspring. This would have allowed a more detailed analysis of potential differences 
between the effects of maternal vs paternal cardio-metabolic risk factors on MA risk in the offspring. 
The lack of an assessment of the offspring in their early adulthood, at the time when the parents were 
assessed, also needs to be acknowledged. However, the main study aim was to assess whether 
parental cardio-metabolic risk factors were more common among young people with T1D who 
developed MA during pubertal years.  
 
Conclusions  
This study showed that MA in young offspring with childhood-onset T1D was associated with an 
abnormal cardio-metabolic profile in the parents, mainly driven by abnormal blood pressure, thus 
highlighting that the familial influence on risk of developing renal complications previously 
described in adult patients with diabetes, exists also in young people with an early onset of T1D.  
These findings underline the importance of considering familial cardio-metabolic risk factors when 
one is estimating the renal risk in young offspring with diabetes. In particular, the characterization of 
familial risk factors predisposing to the development of MA could help in identifying patients at a 
higher risk of developing diabetic complications, who might require more intensive preventive and 
treatment strategies to prevent their development and/or slow their progression.  
Future studies are required to explore whether the reported association is related to a common genetic 
background or might be related to shared lifestyle/sociodemographic factors, which could be targeted 
to reduce DN in offspring with T1D. 
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Table 1. Numbers and characteristics of recruited parents within the ORPS/NFS cohorts 
 Total MA+ group MA- group 
Probands 85 35 50 
Total parents 139 53 86 
Fathers 63 21 42 
Mothers 76 32 44 
Both parents recruited 54 18 36 
Only mothers 22 14 8 
Only fathers 9 3 6 
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Table 2. Characteristics of offspring with microalbuminuria (MA+ group) and 
normoalbuminuria (MA- group)  
 
 MA+ 
group 
MA- 
group 
P value 
N 35 50  
Sex (Males) 8 (23%) 16 (32%) 0.5 
Age at T1D diagnosis (years) 9.3 ± 3.2 8.8 ± 3.3 0.5 
Age at MA onset (years) 17.3 ± 4.5   
T1D duration at MA onset (years) 8.1 ± 4.6   
Age at last visit (years) 19.1 ± 3.0 20.1 ± 3.5 0.2 
Mean HbA1c (%) 9.9 ± 1.6 9.0 ± 1.2 0.006 
BMI (Kg/m2) 23.5 ± 3.8 22.4 ± 3.2 0.19 
Systolic blood pressure (mmHg) 117.3 ± 9.7 113.2 ±10.7 0.08 
Diastolic blood pressure (mmHg)  72.8 ± 6.2 66.8 ± 7.2 <0.001 
logACR 0.495 ± 0.298  -0.735 ± 0.157 <0.001 
Data are mean ± SD. ACR: albumin:creatinine ratio; MA: microalbuminuria; T1D: type 1 diabetes 
BMI, Blood pressure and logACR are mean values during the whole follow up period 
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Table 3. Clinical and biochemical characteristics of the parents of MA positive vs MA negative 
offspring 
 
 MA+ 
group 
MA- 
group 
P value 
N 53 86  
Sex (fathers) 21 (39.6%) 42 (48.8%) 0.3 
Age (years) 56.7 ± 6.2 56.1 ± 6.3 0.5 
Height (cm) 167.8 ± 8.7 170.7 ± 9.0 0.06 
Weight (Kg) 79.8 ± 16.5 80.3 ± 17.4 0.9 
BMI (Kg/m2) 28.3 ± 5.3 27.4 ± 4.7 0.3 
Waist circumference (cm) 95.0 ± 14.0 93.0 ± 14.1 0.08 
Systolic blood pressure (mmHg) 126.2 ± 13.1 124.3 ± 13.2 0.3 
Diastolic blood pressure(mmHg) 76.5 ± 8.2 72.8 ± 7.5 0.005 
Glucose (mmol/l) 5.2 ± 1.7 5.1 ± 0.9 0.7 
Insulin (pmol/l) 37.0 [20.0-57.7] 34.0 [22.0-51.0] 0.6 
HDL cholesterol (mmol/l) 1.5 ± 0.4 1.5 ± 0.4 0.2 
Triglycerides (mmol/l) 0.8 [0.8-1.6] 0.9 [0.7-1.4] 0.2 
ADMA (nmol/L) 465.5 ± 65.1 456.2 ± 58.2 0.4 
hsCRP (mg/L) 0.96 [0.41-1.73] 1.01 [0.52-1.70] 0.9 
ACR (mg/mol) 0.56 [0.44-0.75] 0.58 [0.45-0.88] 0.9 
Hypertension treatment, n (%) 12 (22.6) 9 (10.5) 0.08 
Dyslipidemia treatment, n (%) 10 (18.9) 10 (11.6) 0.3 
Diabetes, n (%) 2 (3.8) 7 (8.1) 0.5 
Data are mean±SD for normal distributed variable or median [Interquartile range] for non-normal distributed 
variables. P values are adjusted for parental age and sex. ACR: albumin creatinine ratio, ADMA: asymmetric 
dimethylarginine, hsCRP: high sensitivity C-reactive protein, MA: microalbuminuria 
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Table 4. Cardiovascular assessments and body composition (DXA) in parents of 
microalbuminuria (MA) positive vs MA negative offspring 
 
 MA+ 
Group (n 53) 
MA- 
Group (n 86) 
P value 
Cardiovascular measures 
cIMT (mm) 0.66 ± 0.14 0.64 ± 0.11 0.3 
Absolute FMD (mm) 0.22 ± 0.12 0.24 ±0.11 0.5 
FMD (%) 6.11 ± 3.33 6.77 ± 3.56 0.3 
FMD/VTI 0.24 ± 0.52 0.22 ±0.24 0.7 
PWV (m/sec)* 7.95 ± 1.86 7.49 ± 1.60 0.7 
DXA measures    
Total Lean mass, kg 46.2 ± 12.2 49.0 ± 11.4 0.2 
Total Fat mass, Kg 28.3 ± 10.3 27.4 ± 10.2 0.6 
Fat mass android, Kg 3.0 ± 1.3 4.8 ± 1.7 0.2 
Fat mass gynoid, Kg 5.1  ± 1.6 4.9 ± 1.7 0.4 
Fat mass trunk, Kg 16.3 ± 6.2 15.4 ± 6.4 0.4 
Fat mass limbs, Kg 11.5 ± 3.9 11.2 ± 4.4 0.6 
P values are adjusted for parental age and sex. * PWV was also adjusted for blood pressure.  
Data are mean±SD. cIMT: carotid intima-media thickness, FMD: flow mediated dilatation, PWV: pulse wave 
velocity; VTI: velocity time integral 
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Figure legend 
 
Figure 1. Cardio-metabolic risk score (CMRS) in parents of MA positive and MA negative 
offspring 
 
 
 
 
 
 
 
 
 
 
 
 
